Clinical Trials Logo

Hemoglobinuria clinical trials

View clinical trials related to Hemoglobinuria.

Filter by:

NCT ID: NCT02605993 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: January 4, 2016
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.

NCT ID: NCT02598583 Completed - PNH Clinical Trials

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: November 12, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.

NCT ID: NCT02591862 Completed - Clinical trials for Paroxysmal Nocturnal Haemoglobinuria (PNH)

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.

NCT ID: NCT02588833 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

PADDOCK
Start date: December 1, 2015
Phase: Phase 1
Study type: Interventional

The objectives of the study are to assess the safety, tolerability, preliminary efficacy and PK of multiple subcutaneous (SC) doses of pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who have not received treatment with eculizumab in the past. An exploratory objective of the study is to assess the pharmacodynamics (PD) of multiple SC doses of pegcetacoplan when administered to PNH patients.

NCT ID: NCT02534909 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria PNH

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: September 9, 2015
Phase: Phase 2
Study type: Interventional

To determine whether LFG316 can induce a hematological response, as measured by reduction in hemolytic activity, in patients with PNH.

NCT ID: NCT02352493 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

Start date: January 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-CC5 in healthy adult volunteers and subjects with PNH

NCT ID: NCT02264639 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

Start date: February 23, 2015
Phase: Phase 1
Study type: Interventional

This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide decisions to further develop the drug.

NCT ID: NCT02179359 Recruiting - Sickle Cell Disease Clinical Trials

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Start date: September 2, 2014
Phase: N/A
Study type: Interventional

This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.

NCT ID: NCT01760096 Active, not recruiting - Thrombosis Clinical Trials

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

Start date: January 2013
Phase: Phase 2
Study type: Interventional

Paroxysmal nocturnal hemoglobinuria is an acquired chronic hemolytic anemia,this study is designed to evaluate the safety and efficacy of Levamisole combined with cyclosporine A in patients with Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the setting of another bone marrow failure syndromes

NCT ID: NCT01642979 Active, not recruiting - Thrombosis Clinical Trials

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria

PNH-2012
Start date: July 2012
Phase: Phase 2
Study type: Interventional

Paroxysmal nocturnal hemoglobinuria is an acquired chronic hemolytic anemia,this study is designed to evaluate the safety and efficacy of Levamisole combined with cyclosporine A in patients with classic paroxysmal nocturnal hemoglobinuria.